ReviewMayo Clinic proceedings2012
Clostridium difficile infection: new insights into management.
Review in Mayo Clinic proceedings, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- The value of fecal calprotectin inFrontiers in physiology · 2022Pooled it
- Acid Suppression Medications During Hospitalization as a Risk Factor for Recurrence of Clostridioides difficile Infection: Systematic Review and Meta-analysis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021Pooled it
- Recommendations for the diagnosis and treatment of Clostridioides difficile infection: An official clinical practice guideline of the Spanish Society of Chemotherapy (SEQ), Spanish Society of Internal Medicine (SEMI) and the working group of Postoperative Infection of the Spanish Society of Anesthesia and Reanimation (SEDAR).Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2020Guideline
- Association of Gastric Acid Suppression With Recurrent Clostridium difficile Infection: A Systematic Review and Meta-analysis.JAMA internal medicine · 2017Pooled it
- Epidemiology ofAntibiotics (Basel, Switzerland) · 2026Article
- Review
- Lurking Danger: Emerging Evidence.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2024Article
- Comparative Genomics of Clostridioides difficile.Advances in experimental medicine and biology · 2024Article
- Review
- An integrated pipeline for prediction of Clostridioides difficile infection.Scientific reports · 2023Article
- Article
- ClostridioidesGastroenterology & hepatology · 2023Article
- Prevalence of Clostridium Difficile Infection (CDI) among Inflammatory Bowel Disease (IBD) Patients in Comparison to Non-IBD Patients in King Abdulaziz Medical City in Jeddah.Interdisciplinary perspectives on infectious diseases · 2023Article
- Review
- Clinical and microbial characterization of toxigenicIranian journal of microbiology · 2020Article
- Physical, Laboratory, Radiographic, and Endoscopic Workup forClinics in colon and rectal surgery · 2020Review
- Fecal microbiota transplantation in recurrentJGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Development and Implementation of Whole Genome Sequencing-Based Typing Schemes forFrontiers in public health · 2019Review
- Proteomic Signatures ofCells · 2018Article
- High rate of Clostridium difficile among young adults presenting with diarrhea at two hospitals in Kenya.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2018Article
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Clostridium difficile was first described as a cause of diarrhea in 1978 and is now among the leading 3 hospital-acquired infections in the United States, along with methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci. In the past 2 decades, there has been an increase in the incidence, severity, and recurrence rates of C difficile infection, all of which are associated with poor outcomes. In addition, several novel risk factors and newer treatment methods are emerging, including fidaxomicin therapy, treatment using monoclonal antibodies, and fecal microbiota transplantation, that have shown promise for the treatment of C difficile infection. This review focuses on the changing epidemiology, risk factors, and newer methods for treatment of C difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.